Clinical translation of autologous Schwann cell transplantation for the treatment of spinal cord injury

Current Opinion in Organ Transplantation

Volumn 18, Issue 6, 2013, Pages 682-689

  Guest, James ^a   Santamaria, Andrea J ^a   Benavides, Francisco D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous; Cell culture; Schwann cell; Spinal cord injury; Transplant

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; AUTOLOGOUS SCHWANN CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CELL CULTURE; CELL DEDIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; EMERGENCY CARE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MYELINATION; NERVE CELL PLASTICITY; NERVE REGENERATION; NERVE TRANSPLANTATION; NEUROIMAGING; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PIA MATER; REVIEW; SCHWANN CELL; SPINAL CORD INJURY; SPINAL CORD REGENERATION;

CELL TRANSPLANTATION; HUMANS; PERIPHERAL NERVES; SCHWANN CELLS; SPINAL CORD INJURIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84888302117     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000026     Document Type: Review

References (48)

1. Arthur-Farraj PJ, Latouche M, Wilton DK, et al. c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron 2012; 75:633-647.
2. Mirsky R, Jessen KR. The neurobiology of Schwann cells. Brain Pathol 1999; 9:293-311.
3. Howell WH, Huber GC. A physiological, histological and clinical study of the degeneration and regeneration in peripheral nerve fibres after severance of their connections with the nerve centres. J Physiol 1892; 13:335-406; 311.
4. Bunge MB, Wood PM. Realizing the maximum potential of Schwann cells to promote recovery from spinal cord injury. Handb Clin Neurol 2012; 109:523-540.
5. Saberi H, Moshayedi P, Aghayan HR, et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett 2008; 443:46-50.
6. Saberi H, Firouzi M, Habibi Z, et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases. J Neurosurg Spine 2011; 15:515-525.
7. Zhou XH, Ning GZ, Feng SQ, et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up. Cell Transplant 2012; 21 (Suppl. 1):S39-S47.
8. Aghayan HR, Arjmand B, Norouzi-Javidan A, et al. Clinical grade cultivation of human Schwann cell, by the using of human autologous serum instead of fetal bovine serum and without growth factors. Cell Tissue Bank 2012; 13:281-285.
9. Eaton DA, Hirsch BE, Mansour OI. Recovery of facial nerve function after repair or grafting: our experience with 24 patients. Am J Otolaryngol 2007; 28:37-41.
10. Garozzo D, Ferraresi S, Buffatti P. Surgical treatment of common peroneal nerve injuries: indications and results. A series of 62 cases. J Neurosurg Sci 2004; 48:105-112; discussion 112.
11. Trumble TE, Vanderhooft E, Khan U. Sural nerve grafting for lower extremity nerve injuries. J Orthop Trauma 1995; 9:158-163.
12. Wood MB. Peroneal nerve repair. Surgical results. Clin Orthop Relat Res 1991; 267:206-210.
13. Levi AD, Guenard V, Aebischer P, Bunge RP. The functional characteristics of Schwann cells cultured from human peripheral nerve after transplantation into a gap within the rat sciatic nerve. J Neurosci 1994; 14:1309-1319.
14. Levi AD, Sonntag VK, Dickman C, et al. The role of cultured Schwann cell grafts in the repair of gaps within the peripheral nervous system of primates. Exp Neurol 1997; 143:25-36.
15. Guest JD, Rao A, Olson L, et al. The ability of human Schwann cell grafts to promote regeneration in the transected nude rat spinal cord. Exp Neurol 1997; 148:502-522.
16. Xu XM, Guenard V, Kleitman N, Bunge MB. Axonal regeneration into Schwann cell-seeded guidance channels grafted into transected adult rat spinal cord. J Comp Neurol 1995; 351:145-160.
17. Fishman PS, Nilaver G, Kelly JP. Astrogliosis limits the integration of peripheral nerve grafts into the spinal cord. Brain Res 1983; 277:175-180.
18. Richardson PM, McGuinness UM, Aguayo AJ. Axons from CNS neurons regenerate into PNS grafts. Nature 1980; 284:264-265.
19. Smith GV, Stevenson JA. Peripheral nerve grafts lacking viable Schwann cells fail to support central nervous system axonal regeneration. Exp Brain Res 1988; 69:299-306.
20. Brockes JP, Fields KL, Raff MC. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 1979; 165:105-118.
21. Casella GT, Bunge RP, Wood PM. Improved method for harvesting human Schwann cells from mature peripheral nerve and expansion in vitro. Glia 1996; 17:327-338.
22. Levi AD, Bunge RP, Lofgren JA, et al. The influence of heregulins on human Schwann cell proliferation. J Neurosci 1995; 15:1329-1340.
23. Hilton DA, Jacob J, Househam L, Tengah C. Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry 2007; 78:1271-1272.
24. Fraher JP. The transitional zone and CNS regeneration. J Anat 2000; 196 (Pt 1):137-158.
25. Fraher JP. The transitional zone and CNS regeneration. J Anat 1999; 194 (Pt 2):161-182.
26. Duncan ID, Hammang JP, Gilmore SA. Schwann cell myelination of the myelin deficient rat spinal cord following X-irradiation. Glia 1988; 1:233-239.
27. Bruce JH, Norenberg MD, Kraydieh S, et al. Schwannosis: role of gliosis and proteoglycan in human spinal cord injury. J Neurotrauma 2000; 17:781-788.
28. Guest JD, Hiester ED, Bunge RP. Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp Neurol 2005; 192:384-393.
29. Kanakis DN, Kamphausen T, Van de Nes J. A 32-year-old male with brainstem lesions. Brain Pathol 2013; 23:101-104.
30. FDA. Guidance for industry: preclinical assessment of investigational cellular and gene therapy products, DRAFT. 2012; http://www.fda.gov/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ CellularandGeneTherapy/default.htm.
31. Bosse R, Kulmburg P, von Kalle C, et al. Production of stem-cell transplants according to good manufacturing practice. Ann Hematol 2000; 79:469-476.
32. Lammertse DP, Jones LA, Charlifue SB, et al. Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord 2012; 50:661-671.
33. Grossman RG, Frankowski RF, Burau KD, et al. Incidence and severity of acute complications after spinal cord injury. J Neurosurg Spine 2012; 17:119-128.
34. Zariffa J, Kramer JL, Fawcett JW, et al. Characterization of neurological recovery following traumatic sensorimotor complete thoracic spinal cord injury. Spinal Cord 2011; 49:463-471.
35. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol 2009; 27:213-214.
36. Frantz S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotechnol 2012; 30:12-13.
37. Lebkowski J. GRNOPC1: the world's first embryonic stem cell-derived therapy Interview with Jane Lebkowski. Regen Med 2011; 6:11-13.
38. Wirth E3rd, Lebkowski JS, Lebacqz K. Response to Frederic Bretzner et al. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 2011; 8:476-478.
39. Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 2012; 30:1144-1151.
40. Riley J, Federici T, Polak M, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery 2012; 71:405-416; discussion 416.
41. Stradiotti P, Curti A, Castellazzi G, Zerbi A. Metal-related artifacts in instrumented spine. Techniques for reducing artifacts in CT and MRI: state of the art. Eur Spine J 2009; 18 (Suppl. 1):102-108.
42. Mann R, Schaefer C, Sadosky A, et al. Burden of spinal cord injury-related neuropathic pain in the United States: retrospective chart review and crosssectional survey. Spinal Cord 2013; 51:564-570.
43. Margot-Duclot A, Tournebise H, Ventura M, Fattal C. What are the risk factors of occurrence and chronicity of neuropathic pain in spinal cord injury patients? Ann Phys Rehabil Med 2009; 52:111-123.
44. Macias MY, Syring MB, Pizzi MA, et al. Pain with no gain: allodynia following neural stem cell transplantation in spinal cord injury. Exp Neurol 2006; 201:335-348.
45. Monje PV, Soto J, Bacallao K, Wood PM. Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: role of cAMP and JNK in the maintenance of the differentiated state. J Biol Chem 2010; 285:31024-31036.
46. Guest J, Benavides F, Padgett K, et al. Technical aspects of spinal cord injections for cell transplantation. Clinical and translational considerations. Brain Res Bull 2011; 84:267-279.
47. Federici T, Hurtig CV, Burks KL, et al. Surgical technique for spinal cord delivery of therapies: demonstration of procedure in Gottingen minipigs. J Vis Exp 2012; 70:e4371.
48. Riley JP, Raore B, Taub JS, et al. Platform and cannula design improvements for spinal cord therapeutics delivery. Neurosurgery 2011; 69:ons147-ons154; discussion ons155.